Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
暂无分享,去创建一个
B. Fox | J. Dipersio | P. Moore | J. Wigginton | C. Bifulco | H. Lelièvre | N. Vey | C. Ballesteros-Merino | E. Bonvini | J. Davidson-Moncada | D. Li | Ross La Motte-Mohs | J. Muth | Jichao Sun | M. Rettig | J. Godwin | D. Primo | J. Baughman | J. Ballesteros | Daner Li